Onward medical provides preliminary q3 2025 update highlighting accelerating arc-ex adoption in the united states

Eindhoven, the netherlands, oct. 13, 2025 (globe newswire) -- onward medical n.v. (euronext: onwd – us adr: onwry), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (sci) and other movement disabilities, today announces the following key achievements in the third quarter of 2025:
ARC Ratings Summary
ARC Quant Ranking